Mizuho analyst Difei Yang says Zogenix remains one of her top picks in 2019. Fintepla's "unique" mechanism of action has been a key part of the "impressive" data observed in Dravet syndrome, a relatively homogeneous disease, Yang tells investors in a research note. She believes data in new indications "will be an important part of the story" and reiterates a Buy rating on Zogenix with a $69 price target.
https://thefly.com/landingPageNews.php?id=2877565
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.